OUR TEAM

Andrew Roper

Partner

Andrew Roper

Partner

Andrew Roper’s strong technical ability, combined with his talent for drawing out the right facts, turns seemingly difficult cases into straightforward cases.
Andrew Roper’s strong technical ability, combined with his talent for drawing out the right facts, turns seemingly difficult cases into straightforward cases.

OVERVIEW

Andrew Roper is a partner in Haug Partners’ New York offices. The majority of his practice focuses on patent litigation. Additionally, he performs due diligences, and evaluations of IP assets. Mr. Roper also regularly works on appellate matters before the Federal Circuit.

REPRESENTATIVE CASES

  • Takeda Pharm. Co. v. Norwich Pharms., Inc., 2022 U.S. Dist. LEXIS 231773, 2022 WL 17959811 (D.N.J. Dec. 27, 2022) (trial victory on all asserted claims from 9 asserted patents including claims directed to the compound, prodrug technology, salts, methods of treatment, pharmacokinetics, pharmacodynamics, water content, and formulation)
  • Astellas US LLC v. Hospira, Inc., No. CV 18-1675-CFC, 2022 WL 1591277 (D. Del. May 19, 2022) (finding Curia’s API and manufacturing process do not infringe polymorph patents)
  • Takeda Pharm. Co. Ltd. v. Norwich Pharms., Inc., No. CV 20-8966 (SRC), 2022 WL 621041 (D.N.J. Mar. 3, 2022) (“In largest part, this is a battle of the experts, a battle which Plaintiffs clearly win.”)
  • NOF Corp. v. Nektar Therapeutics, No. IPR2019-01397, 2021 WL 3438554 (P.T.A.B. Aug. 5, 2021) (key claims to branched-PEG-malemide polymers patentable);
  • CSL Behring Gmbh v. Shire Viropharma Inc., No. IPR2019-00459, 2019 WL 2866004 (P.T.A.B. July 2, 2019) (institution denied on patent covering biologic treatment);
  • Supernus Pharms., Inc. v. TWi Pharms., Inc., 265 F. Supp. 3d 490, (trial victory aff’d Supernus Pharms. Inc. v. TWi Pharms. Inc, 2018 U.S. App. LEXIS 25271 (Fed. Cir. Sept. 6, 2018); §285 attorney’s fees awarded based on “overwhelming” trial evidence ECF No. 420-4 (D.N.J. June 27, 2019));
  • CSL Behring v Shire Viropharma Inc. 2017 Pat. App. LEXIS 13304, *1-2 (P.T.A.B. December 7, 2017) (institution denied on patent covering subcutaneous biologic formulation);
  • Supernus Pharms., Inc. v. Actavis Inc., 2016 U.S. Dist. LEXIS 30444 (D.N.J. Mar. 9, 2016) (trial victory aff’d Supernus Pharms., Inc. v. Actavis Inc., 665 Fed. Appx. 901 (Fed. Cir. Dec. 12, 2016));
  • Shire LLC v. Amneal Pharms., LLC, 2014 U.S. Dist. LEXIS 85369 (D.N.J. June 23, 2014) (summary judgment victory aff’d Shire, LLC v. Amneal Pharms., LLC, 802 F.3d 1301 (Fed. Cir. 2015));
  • Otter Prods., LLC v. United States, 37 F. Supp. 3d 1306 (Ct. Int’l Trade 2014); Otter v. ITC and Speculative Product Design, No. 14-1480, ECF Nos. 25, 34 (Fed. Cir. 2014) (denying emergency motions to stay enforcement of US Customs and Border Protection’s ITC General Exclusion Order);
  • Duramed Pharms., Inc. v. Paddock Labs., Inc., 715 F. Supp. 2d 552 (S.D.N.Y. 2010) (summary judgment victory aff’d Duramed Pharms., Inc. v. Paddock Labs., Inc., 2011 U.S. App. LEXIS 3384 (Fed. Cir. Feb. 17, 2011).
VIEW ALL

EDUCATION

  • Case Western Reserve University, (B.S.E., Chemical Engineering, 2004)
  • University of Virginia School of Law, (J.D., 2007)

BAR ADMISSIONS

  • New York
  • Eastern District of New York
  • Southern District of New York
  • United States Court of Appeals for the Federal Circuit
  • Court of International Trade
  • Registered to practice before the U.S. Patent and Trademark Office
VIEW ALL

MEMBERSHIPS

  • New York Intellectual Property Law Association
  • Federal Circuit Bar Association

CONTACT

LOCATION

New York City
745 Fifth Avenue, 10th Floor, 
New York, NY 10151
745 Fifth Avenue, 10th Floor, New York, NY 10151